Posted by jay on September 27, 2005, at 15:44:28
In reply to Re: Triple Reuptake Inhibitors - Race to Market, posted by SLS on September 27, 2005, at 10:30:32
> > not to be cynical again, but i am very skeptical that anything actually dopaminergic will ever hit the market.
>I am also skeptical, as I honestly am not convinced dopamine reuptake inhibition is really what is needed.
To me, I am of the thought that depression and anxiety are two heads of the same coin. It is interesting that they now have revealed Anxiety as a symptom as being linked to Bipolar and even Schizophrenia. That is why I have more faith in the area of dopamine/serotonin *modulation*...or best yet...*balance*.. than anything. Also, each of the different subtypes of receptors need to be explored. I really thought we where going in the right direction with meds like Serzone possibly combined with an SNRI/SRI, as well as combos involving Abilify and Zyprexa, and even the older often-bashed, Buspar. On top of this, the benzos seem to be the *ultimate* meds that bring balance...especially to the anxiety producing effects of antidepressants.
So, we need a massive plethora of agonists and antagonists that work at a multitude of receptor sites. We must go beyond looking at some simple model that says we simply need to increase *this* or *that* NT. I feel it is the receptor subtypes that will lead us in the direction to tackle more specific symptoms. We should go beyond just *topping up* on dopamine, or serotonin (where did that get us?), etc.
IMHO...respectfully
Jay
poster:jay
thread:560146
URL: http://www.dr-bob.org/babble/20050927/msgs/560252.html